REG - Verici Dx PLC - Significant milestone re Thermo Fisher agreement

Verici DxAnnouncement

01/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240701:nRSA4775Ua&default-theme=true

RNS Number : 4775U  Verici Dx PLC  01 July 2024

Verici Dx plc

("Verici Dx" or the "Company")

 

Achievement of significant milestone under Thermo Fisher Scientific agreement

Successful transfer of pre-transplant prognostic testing technology

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, notes that Thermo Fisher Scientific has confirmed the
completion of the transfer and achievement of all transfer-related activities
for the pre-transplant prognostic testing technology licensed by the Company
to Thermo Fisher Scientific under the terms of a global licensing and
commercialisation agreement announced on 15 November 2023 (the
"Agreement")(1).

 

This enables Thermo Fisher Scientific to use the technology to develop a LDT
("Laboratory Developed Test") in its own labs. This event triggers a further
milestone payment under the Agreement, in line with previously disclosed
expectations.

 

Commenting on the milestone, Sara Barrington, CEO of Verici Dx, said:

 

"I am delighted to announce this smooth transition between Verici Dx and
Thermo Fisher Scientific. This collaboration brings together Verici Dx's
innovative technology into Thermo Fisher's new CLIA laboratory in the U.S.,
which will ultimately benefit patients and the field of organ
transplantation."

 

This announcement contains inside information for the purposes of Article 7 of
the UK Market Abuse Regulation (UK MAR). Upon the publication of this
announcement, this inside information is now considered to be in the public
domain.

 

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     investors@vericidx.com
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Aubrey Powell / Sam Butcher

 

 

Notes

1.     Please refer to RNS number 4652T for further information. A copy of
this announcement can also be found on the company website
https://verici-dx-plc.flint-platform.com/regulatory-news/62760
(https://verici-dx-plc.flint-platform.com/regulatory-news/62760)

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRSDEFWSELSEIM